BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025
BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.
Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $33
Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $28 to $33.
Raymond James Maintains Strong Buy on Globe Life, Lowers Price Target to $138
Raymond James analyst Wilma Burdis maintains Globe Life (NYSE:GL) with a Strong Buy and lowers the price target from $141 to $138.
Janney Montgomery Scott Downgrades Hancock Whitney to Neutral, Announces $44.5 Price Target
Janney Montgomery Scott analyst Christopher Marinac downgrades Hancock Whitney (NASDAQ:HWC) from Buy to Neutral and announces $44.5 price target.
Citigroup Maintains Buy on Luminar Technologies, Lowers Price Target to $19
Citigroup analyst Itay Michaeli maintains Luminar Technologies (NASDAQ:LAZR) with a Buy and lowers the price target from $20 to $19.
Citigroup Maintains Buy on Kinetik Holdings, Lowers Price Target to $34
Citigroup analyst Spiro Dounis maintains Kinetik Holdings (NYSE:KNTK) with a Buy and lowers the price target from $35 to $34.
Needham Downgrades Momentive Glb to Hold
Needham analyst Ryan MacDonald downgrades Momentive Glb (NASDAQ:MNTV) from Buy to Hold.
HSBC Maintains Buy on Lufax Holding, Lowers Price Target to $3
HSBC analyst Carson Lo maintains Lufax Holding (NYSE:LU) with a Buy and lowers the price target from $4 to $3.
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $26
HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $27 to $26.